Search

Your search keyword '"Stubbs, Matthew"' showing total 425 results

Search Constraints

Start Over You searched for: Author "Stubbs, Matthew" Remove constraint Author: "Stubbs, Matthew"
425 results on '"Stubbs, Matthew"'

Search Results

101. Whole-genome sequencing of a sporadic primary immunodeficiency cohort

102. Germline mutations in the transcription factor IKZF5 cause thrombocytopenia

103. Identification of a homozygous recessive variant in PTGS1 resulting in a congenital aspirin-like defect in platelet function

104. De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures

106. Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (vol 8, 1300, 2018)

108. Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome

110. Erratum to: Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (Scientific Reports, (2018), 8, 1, (1300), 10.1038/s41598-017-14403-y)

111. Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data

113. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

114. TARGETING IN OUTER SPACE: AN EXPLORATION OF REGIME INTERACTIONS IN THE FINAL FRONTIER.

115. The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

117. Administration of immunoglobulin G‐degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti‐ ADAMTS 13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission

120. De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures

127. Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies

128. Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification

130. Abstract 2100: Selective inhibition of FGFR4 by INCB062079 is efficacious in models of FGF19- and FGFR4-dependent cancers

131. Abstract 2032: Combination of epigenetic regulation via LSD1 inhibition with signal transduction inhibitors significantly enhances anti-tumor activity in models of hematologic malignancies

132. Abstract 3726: INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit expansion of AML

133. Abstract 143: Preclinical studies on potential therapeutic combination partners for the potent and selective PI3Kδ inhibitor INCB050465 in DLBCL

135. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δInhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy▪

136. Administration of immunoglobulin G‐degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti‐ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.

137. PROFESSOR IVAN SHEARER AM RFD FAAL RAN (RTD) 1938 - 2019.

139. Abstract 4702: Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo

140. Abstract 4712: Discovery of INCB059872, a novel FAD-directed LSD1 inhibitor that is effective in preclinical models of human and murine AML

141. Abstract 3780: Activity of the BET inhibitor INCB054329 in models of lymphoma

142. Abstract 4904: The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models

143. Book Reviews

145. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

146. Germline mutations in the transcription factor IKZF5 cause thrombocytopenia

147. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

148. Disclosure, Not Disqualification: A Democratic Proposal to Promote the Fidelity of Elected Representatives to the People.

149. The Adaptation Of Ideas In Urban Development - Case Study: Expo 2010, Shanghai, P.R. China

150. Abstract 3525: The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models

Catalog

Books, media, physical & digital resources